[
  {
    "compound": "AAA",
    "indication": "blastic plasmacytoid dendritic cell neoplasm",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Nell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell.\n&lt;/p&gt;&lt;p&gt;TAGRAXOFUSP was approved by the U.S. FDA in 2018 for the treatment of adult and pediatric patients, 2 years or older, with BPDCN.\n &lt;/p&gt;\n\t&lt;p&gt;\n              &lt;a href=\"https://www.elzonris.com/hcp/content/documents/ELZONRIS_US_Full_Prescribing_Information.pdf\" target=\"_blank\"&gt;Important Safety Information &lt;/a&gt;\n          &lt;/p&gt;\n&lt;table class=\"genericInfo\"&gt;\n\t&lt;tbody&gt;\n\t\t&lt;tr&gt;\n\t\t\t&lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n\t\t\t&lt;td&gt;Breakthrough Therapy Designation and Orphan Drug Designation&lt;br /&gt;&lt;/td&gt;\n\t\t&lt;/tr&gt;\n\t&lt;/tbody&gt;\n&lt;/table&gt;&lt;p&gt;&lt;br /&gt;&lt;/p&gt;\n\n\n&lt;p&gt;In Europe, on January 2021 TAGRAXOFUSP was approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN.\n\n&lt;/p&gt;\n&lt;p&gt;\n              &lt;a href=\"https://ec.europa.eu/health/documents/community-register/2021/20210107150127/anx_150127_en.pdf\" target=\"_blank\"&gt;Important Safety Information &lt;/a&gt;\n          &lt;/p&gt;\n&lt;table class=\"genericInfo\"&gt;\n\t&lt;tbody&gt;\n\t\t&lt;tr&gt;\n\t\t\t&lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_EU.svg\" alt=\"\" /&gt;&lt;/td&gt;\n\t\t\t&lt;td&gt;Orphan Drug Designation&lt;br /&gt;&lt;/td&gt;\n\t\t&lt;/tr&gt;\n\t&lt;/tbody&gt;\n&lt;/table&gt;&lt;p&gt;&lt;br /&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=\"https://youtu.be/rnuLOhUGqzI\" target=\"_blank\"&gt;MECHANISM OF ACTION&lt;/a&gt;&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "BBB",
    "indication": "blastic plasmacytoid dendritic cell neoplasm",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Nell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. \n&lt;br /&gt;In Europe, on January 2021 TAGRAXOFUSP has been approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN.\n&lt;/p&gt;\n\t&lt;p&gt;\n              &lt;a href=\"https://ec.europa.eu/health/documents/community-register/2021/20210107150127/anx_150127_en.pdf\" target=\"_blank\"&gt;Important Safety Information &lt;/a&gt;\n          &lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n\t&lt;tbody&gt;\n\t\t&lt;tr&gt;\n\t\t\t&lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_EU.svg\" alt=\"\" /&gt;&lt;/td&gt;\n\t\t\t&lt;td&gt;Orphan Drug Designation&lt;br /&gt;&lt;/td&gt;\n\t\t&lt;/tr&gt;\n\t&lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "BBB",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "Targeted biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "IST",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "CCC",
    "indication": "chronic myelomonocytic leukemia",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies. It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. \n&lt;br /&gt;TAGRAXOFUSP is now being investigated for the treatment of chronic myelomonocytic leukemia.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "CCC",
    "indication": "myelofibrosis",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies. It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. \n&lt;br /&gt;TAGRAXOFUSP is now being investigated for the treatment of Myelofibrosis.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "CCC",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "SME (HDACi)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "DDD",
    "indication": "myelodysplastic syndrome",
    "mechanismofaction": "SME (HDACi)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Pracinostat is an inhibitor of class I, II, and IV histone deacetylase (HDAC) with very favorable pharmacokinetic properties respect to other HDACi. \n&lt;br /&gt;Through the inhibition of HDACs histones are acetylated, resulting in opening of the chromatin, nucleosome remodeling and transcriptional activation.  The accumulation of acetylated histones leads to increased transcription of a subset of genes, (including tumors suppressor genes) which in turn results in cell-growth arrest, differentiation, and/or induction of cells apoptosis.\n&lt;br /&gt;Pracinostat is currently being tested for the treatment of newly diagnosed, naïve patients with higher risk MDS.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "DDD",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "SME (PIM/FLT3i)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases.\n&lt;br /&gt;FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents.\n&lt;br /&gt;The spectrum of activity of MEN1703 also warrants the compound investigation in AML patients regardless of FLT3 aberrations.\n&lt;br /&gt;MEN1703 is being investigated as potential treatment for adult patients with relapsed/refractory AML.\n&lt;/p&gt;\n&lt;table class=\"genericInfo\"&gt;\n\t&lt;tbody&gt;\n\t\t&lt;tr&gt;\n\t\t\t&lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n\t\t\t&lt;td&gt;Orphan Drug Designation&lt;br /&gt;&lt;/td&gt;\n\t\t&lt;/tr&gt;\n\t&lt;/tbody&gt;\n&lt;/table&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "DDD",
    "indication": "breast cancer",
    "mechanismofaction": "SME (PI3Ki)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1611 is a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a novel chemical structure targeting the α, β and γ isoforms while sparing the δ, with a novel chemical structure.\n&lt;br /&gt;The PI3K/Akt pathway regulates various cellular processes such as proliferation, growth, apoptosis and cytoskeletal rearrangement. Various types of cancers are thought to be “addicted” to PI3K/Akt pathway signaling and therefore inhibition of PI3K is a potent therapeutic strategy for fighting cancer.\n&lt;br /&gt;MEN1611 is being investigated as a potential treatment for patients with PIK3CA-mutated, HER2-positive, advanced or metastatic breast cancer who have failed anti-HER2 based therapy.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "DDD",
    "indication": "colorectal cancer",
    "mechanismofaction": "SME (PI3Ki)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1611 is a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a novel chemical structure targeting the α, β and γ isoforms while sparing the δ, with a novel chemical structure.\nThe PI3K/Akt pathway regulates various cellular processes such as proliferation, growth, apoptosis and cytoskeletal rearrangement. Various types of cancers are thought to be “addicted” to PI3K/Akt pathway signaling and therefore inhibition of PI3K is a potent therapeutic strategy for fighting cancer.\n&lt;br /&gt;MEN1611 is being investigated as a potential treatment for patients with PIK3CA mutated, K-RAS, N-RAS and B-RAF wild-type metastatic colorectal cancer, failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "EEE",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "mAB (Anti-CD157)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1112 is a humanized, CD157-specific, monoclonal IgG1 antibody. CD157 represents a therapeutic target in AML since it is broadly expressed in leukemic blast cells from peripheral blood and from bone marrow, both at diagnosis and at disease relapse. Upon binding, MEN1112 specifically induces antibody-dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells.\nMEN1112 is currently being investigated as potential treatment for patients with relapsed/refractory AML.\n\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "EEE",
    "indication": "solid tumors",
    "mechanismofaction": "ADC (Anti-CD205)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its target, the MEN1309/CD205 complex is rapidly internalized in antigen expressing cells where it can exert its cytotoxic activity. \nMEN1309 is currently being tested as a potential treatment for patients with solid tumors.\n\n\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "EEE",
    "indication": "solid tumors",
    "mechanismofaction": "SME (XP01i)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nFELEZONEXOR (SL-801) is a novel, oral, small-molecule reversible inhibitor of exportin-1 (XPO1), a key nuclear transport protein. XPO1 is overexpressed by many cancers, leading to mislocalization of key tumor suppressors and growth-regulatory proteins in the cytoplasm.\nFELEZONEXOR is currently being tested as a potential treatment for patients with solid tumors.\n\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "EEE",
    "indication": "solid tumors",
    "mechanismofaction": "SME (PI3Ki)",
    "enablestage1": "true",
    "enablestage2": "false",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nSL-901 is an oral small molecule PI3K and DNA-PK inhibitor that has demonstrated activity against PI3K α/δ and PIK3C2 β. SL-901 has shown preclinical activity against a variety of tumor types. A Phase 1 trial in patients with solid tumors is currently enrolling.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "FFF",
    "indication": "solid tumors",
    "mechanismofaction": "SME (RETi)",
    "enablestage1": "true",
    "enablestage2": "false",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nSL-1001 is a selective, small molecule RET inhibitor that has demonstrated preclinical activity in a variety of RET-driven tumor models. SL-1001 is currently in IND-enabling studies. \n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "FFF",
    "indication": "Glioblastoma",
    "mechanismofaction": "Immunotherapy (IL-13Rα2, EphA2, Survivin)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;SL-701 is an off-the-shelf, systemically delivered (subcutaneous) immunotherapy designed to direct the immune system to attack targets present on certain malignancies, including brain cancer.&lt;/p&gt;&lt;p&gt;SL-701 is composed of three short peptides (IL-13Rα2, EphA2, and Survivin), targeting glioma-associated antigens and designed to generate an antigen specific CD8+ T cell response.&lt;br /&gt;SL-701 is currently being investigated for the treatment of recurrent glioblastoma multiforme.&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "FFF",
    "indication": "colorectal cancer",
    "mechanismofaction": "SME (PI3Ki)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1611 is a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a novel chemical structure targeting the α, β and γ isoforms while sparing the δ, with a novel chemical structure.\nThe PI3K/Akt pathway regulates various cellular processes such as proliferation, growth, apoptosis and cytoskeletal rearrangement. Various types of cancers are thought to be “addicted” to PI3K/Akt pathway signaling and therefore inhibition of PI3K is a potent therapeutic strategy for fighting cancer.\n&lt;br /&gt;MEN1611 is being investigated as a potential treatment for patients with PIK3CA mutated, K-RAS, N-RAS and B-RAF wild-type metastatic colorectal cancer, failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "GGG",
    "indication": "breast cancer",
    "mechanismofaction": "SME (PI3Ki)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "false",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;\nMEN1611 is a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor with a novel chemical structure targeting the α, β and γ isoforms while sparing the δ, with a novel chemical structure.\n&lt;br /&gt;The PI3K/Akt pathway regulates various cellular processes such as proliferation, growth, apoptosis and cytoskeletal rearrangement. Various types of cancers are thought to be “addicted” to PI3K/Akt pathway signaling and therefore inhibition of PI3K is a potent therapeutic strategy for fighting cancer.\n&lt;br /&gt;MEN1611 is being investigated as a potential treatment for patients with PIK3CA-mutated, HER2-positive, advanced or metastatic breast cancer who have failed anti-HER2 based therapy.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "GGG",
    "indication": "breast cancer",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer. .&lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n    &lt;tbody&gt;\n        &lt;tr&gt;\n            &lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n            &lt;td&gt;Fast Track Designation&lt;/td&gt;\n        &lt;/tr&gt;\n    &lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "GGG",
    "indication": "breast cancer",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.&nbsp;&lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n    &lt;tbody&gt;\n        &lt;tr&gt;\n            &lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n            &lt;td&gt;Fast Track Designation&lt;/td&gt;\n        &lt;/tr&gt;\n    &lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "HHH",
    "indication": "Glioblastoma",
    "mechanismofaction": "Immunotherapy (IL-13Rα2, EphA2, Survivin)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;SL-701 is an off-the-shelf, systemically delivered (subcutaneous) immunotherapy designed to direct the immune system to attack targets present on certain malignancies, including brain cancer.&lt;/p&gt;&lt;p&gt;SL-701 is composed of three short peptides (IL-13Rα2, EphA2, and Survivin), targeting glioma-associated antigens and designed to generate an antigen specific CD8+ T cell response.&lt;br /&gt;SL-701 is currently being investigated for the treatment of recurrent glioblastoma multiforme.&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "HHH",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies. It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell.&lt;br /&gt;\nTAGRAXOFUSP is now being investigated for the treatment of Acute Myeloid Leukemia.",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "III",
    "indication": "chronic myelomonocytic leukemia",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies. It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. \n&lt;br /&gt;TAGRAXOFUSP is now being investigated for the treatment of chronic myelomonocytic leukemia.\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "III",
    "indication": "acute myeloid leukemia",
    "mechanismofaction": "Targeted Biologic (CD123)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies. It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell.&lt;/p&gt;\n&lt;p&gt;TAGRAXOFUSP is now being investigated for the treatment of Acute Myeloid Leukemia.&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "LLL",
    "indication": "breast cancer",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.\n&lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n    &lt;tbody&gt;\n        &lt;tr&gt;\n            &lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n            &lt;td&gt;Fast Track Designation&lt;/td&gt;\n        &lt;/tr&gt;\n    &lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "LLL",
    "indication": "breast cancer",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.\n&lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n    &lt;tbody&gt;\n        &lt;tr&gt;\n            &lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n            &lt;td&gt;Fast Track Designation&lt;/td&gt;\n        &lt;/tr&gt;\n    &lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "LLL",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.&nbsp;&lt;/p&gt;\n\n&lt;table class=\"genericInfo\"&gt;\n    &lt;tbody&gt;\n        &lt;tr&gt;\n            &lt;td&gt;&lt;img src=\"/Portals/31/Images/innovation_research/pipeline/flag_USA.svg\" alt=\"\" /&gt;&lt;/td&gt;\n            &lt;td&gt;Fast Track Designation&lt;/td&gt;\n        &lt;/tr&gt;\n    &lt;/tbody&gt;\n&lt;/table&gt;&lt;br /&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "LLL",
    "indication": "Breast cancer Combination&nbsp;",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELECTRA Trial is An Open-label Multicenter Phase 1b/2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor positive, HER-2 Negative Breast Cancer. ELECTRA is a Global Study with the aim of determining the activity of elacestrant in combination with Abemaciclib in BC EH+/HER2- with brain metastases\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "MMM",
    "indication": "Breast cancer Combination&nbsp;",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELEVATE Trial is A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in various combination in patients with ER+/HER2- metastatic Breast Cancer. ELEVATE is a Global Study which the aim of determining safety and efficacy of combining elacestrant with other agents in the metastatic setting    \n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "MMM",
    "indication": "Breast cancer Combination&nbsp;",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELEVATE Trial is A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in various combination in patients with ER+/HER2- metastatic Breast Cancer. ELEVATE is a Global Study which the aim of determining safety and efficacy of combining elacestrant with other agents in the metastatic setting    \n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "MMM",
    "indication": "Breast cancer Combination&nbsp;",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELECTRA Trial is An Open-label Multicenter Phase 1b/2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor positive, HER-2 Negative Breast Cancer. ELECTRA is a Global Study with the aim of determining the activity of elacestrant in combination with Abemaciclib in BC EH+/HER2- with brain metastases\n&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "NNN",
    "indication": "Breast cancer Combination&nbsp;",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELCIN Trial is an open-label multicenter Ph 2 trials of Elacestrant in women and men with CDK4/6 inhibitor naïve ER+/HER2- metastatic breast cancer. The study investigates elacestrant as single agent without prior CDK4/6i exposure&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "NNN",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.&nbsp;&lt;/p&gt;\n\n&lt;p&gt;ORSERDU was approved by the U.S. FDA in 2023 for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.    \n&lt;/p&gt;\n\n&lt;p&gt;\n&lt;a href=\"https://drive.google.com/file/d/1aE_1XYQqLKDZZZQIOMqU-a-VhQUGIT8w/view\"&gt;Review Prescribing Information&lt;/a&gt;  &lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "OOO",
    "indication": "Multiple Myeloma",
    "mechanismofaction": "XPO1 inhibitor",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;NEXPOVIO® is a first-in-class, oral exportin 1 (XPO1) inhibitor. &nbsp;XPO1 is a nuclear exporter protein that transport from the nucleus to the cytoplasm several proteins, including tumor suppressors, oncogenes, and proteins involved in governing cell growth; it is often overexpressed, and its function mis-regulated in several types of cancers.&lt;/p&gt;\n&lt;p&gt;By inhibiting the XPO1 protein, tumor suppressors proteins buildup in the nucleus of malignant cells and reduce levels of oncogene products which drive cell proliferation. This ultimately leads to cell cycle arrest and death of cancer cells by apoptosis.&lt;/p&gt;\n&lt;p&gt;&lt;br /&gt;&lt;/p&gt;\n&lt;p&gt;NEXPOVIO® was approved by the U.S. FDA in 2019 for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.&lt;/p&gt;\n&lt;p&gt;&lt;a href=\"https://www.xpoviopro.com/\" target=\"_blank\"&gt;Important Safety Information&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=\"https://www.xpoviopro.com/\" target=\"_blank\"&gt;&lt;/a&gt;&lt;span&gt;&nbsp;US – &lt;/span&gt;&lt;span&gt;Fast Track Approval and Orphan Drug Designation&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;&nbsp;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span&gt;NEXPOVIO® was approved in Europe on March 2021 by the EMA as combination therapy with:&lt;/span&gt;&lt;/p&gt;&lt;ul&gt;\n\t\t\t&lt;li&gt;&lt;span&gt;bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and combination therapy. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;\n\t\t&lt;p&gt;&lt;span&gt;&lt;a href=\"https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf\" target=\"_blank\"&gt;&lt;span&gt;Important Safety Information&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;a href=\"https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf\" target=\"_blank\"&gt;&lt;/a&gt;&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "OOO",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.&nbsp;&lt;/p&gt;\n\n&lt;p&gt;ORSERDU was approved by the U.S. FDA in 2023 for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.    \n&lt;/p&gt;\n\n&lt;p&gt;\n&lt;a href=\"https://drive.google.com/file/d/1aE_1XYQqLKDZZZQIOMqU-a-VhQUGIT8w/view\"&gt;Review Prescribing Information&lt;/a&gt;  &lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "OOO",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "true",
    "enablestage5": "true",
    "enablestage6": "true",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. Indeed, Elacestrant has been the first oral SERD to show positive results in a pivotal, phase III trial as a monotherapy versus standard of care for the treatment of ER+/ HER2- advanced or metastatic breast cancer.&nbsp;&lt;/p&gt;\n\n&lt;p&gt;ORSERDU was approved by the U.S. FDA in 2023 for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.    \n&lt;/p&gt;\n\n&lt;p&gt;\n&lt;a href=\"https://drive.google.com/file/d/1aE_1XYQqLKDZZZQIOMqU-a-VhQUGIT8w/view\" target=\"”_blank”\"&gt;Review Prescribing Information&lt;/a&gt;  &lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "OOO",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELCIN Trial is an open-label multicenter Ph 2 trials of Elacestrant in women and men with CDK4/6 inhibitor naïve ER+/HER2- metastatic breast cancer. The study investigates elacestrant as single agent without prior CDK4/6i exposure&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  },
  {
    "compound": "PPP",
    "indication": "Breast cancer Monotherapy",
    "mechanismofaction": "SERD (ER)",
    "enablestage1": "true",
    "enablestage2": "true",
    "enablestage3": "true",
    "enablestage4": "false",
    "enablestage5": "false",
    "enablestage6": "false",
    "enablestage7": "false",
    "status": "open",
    "clinicaltrails": "https://www.clinicaltrials.com",
    "targetclinicaltrials": "_blank",
    "labelclinicaltrials": "Clinical Trials",
    "readmore": "&lt;p&gt;ELCIN Trial is an open-label multicenter Ph 2 trials of Elacestrant in women and men with CDK4/6 inhibitor naïve ER+/HER2- metastatic breast cancer. The study investigates elacestrant as single agent without prior CDK4/6i exposure&lt;/p&gt;",
    "description": "&lt;p&gt;Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed sit amet dolor vel enim blandit tristique. Quisque blandit, nulla vel placerat elementum, mi nisl pulvinar tortor, non bibendum odio ipsum eu odio.&lt;/p&gt;"
  }
]
